CB 30865
Alternative Names: ZM 242421Latest Information Update: 09 Aug 2000
At a glance
- Originator AstraZeneca; Cancer Research UK Centre for Cancer Therapeutics
- Class Antineoplastics; Quinazolines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Aug 2000 Discontinued-Preclinical for Cancer in United Kingdom (Unknown route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 14 Sep 1998 Profile reviewed